Dr Nicholas Salgia speaks to ecancer about the phase III COSMIC-313 trial.

He says that in this trial they evaluated the Genomic Dedifferentiation Signature as a tool to predict which patients benefit most from treatment combinations.

Findings show that patients with low GDS scores had significantly better response rates when treated with cabozantinib combined with nivolumab and ipilimumab compared to immunotherapy alone.

In contrast, patients with high GDS scores had worse overall survival outcomes, highlighting its role as a negative prognostic marker.

This discussion focuses on how genomic profiling may help guide first-line treatment decisions and move the field closer to more personalised therapy strategies in advanced kidney cancer.